Session

PP 05 IBD (Posters)

GENERATION, CHARACTERIZATION AND SCREENING OF ENT001 A NEW THERAPEUTIC TOOL FOR IBD
GENERATION, CHARACTERIZATION AND SCREENING OF ENT001 A NEW THERAPEUTIC TOOL FOR IBD

ARTIFICIAL INTELLIGENCE IN THE DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASES AND IRRITABLE BOWEL SYNDROME
ARTIFICIAL INTELLIGENCE IN THE DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY BOWEL DISEASES AND IRRITABLE BOWEL SYNDROME

FACTORS ASSOCIATED WITH ABDOMINAL PAIN IN PATIENTS WITH ULCERATIVE COLITIS
FACTORS ASSOCIATED WITH ABDOMINAL PAIN IN PATIENTS WITH ULCERATIVE COLITIS

COST AND CONVENIENCE: MAJOR DRIVERS OF PATIENT PREFERENCE ON ROUTE OF BIOLOGIC ADMINISTRATION
COST AND CONVENIENCE: MAJOR DRIVERS OF PATIENT PREFERENCE ON ROUTE OF BIOLOGIC ADMINISTRATION

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

INTESTINE-SPECIFIC DELETION OF TNK1 KINASE AMELIORATES COLITIS BY MODULATING MICROBIOTA COMPOSITION
INTESTINE-SPECIFIC DELETION OF TNK1 KINASE AMELIORATES COLITIS BY MODULATING MICROBIOTA COMPOSITION

ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY
ONE-YEAR INTESTINAL ULTRASOUND IMPROVEMENTS IN UC PATIENTS ON BIOLOGIC OR JAKI THERAPY – INTERIM RESULTS OF THE TRUST BEYOND STUDY

EARLY LIFE EMULSIFIER EXPOSURE INDUCES DYSBIOSIS AND DEFECTIVE INTESTINAL BARRIER IN THE OFFSPRING
EARLY LIFE EMULSIFIER EXPOSURE INDUCES DYSBIOSIS AND DEFECTIVE INTESTINAL BARRIER IN THE OFFSPRING

SUSTAINABILITY OF BIOLOGIC TREATMENT IN PAEDIATRIC PATIENTS WITH CROHN’S DISEASE: ANALYSIS BASED ON THE CZECH NATIONAL REGISTRY
SUSTAINABILITY OF BIOLOGIC TREATMENT IN PAEDIATRIC PATIENTS WITH CROHN’S DISEASE: ANALYSIS BASED ON THE CZECH NATIONAL REGISTRY

RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE
RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE

TREATMENT OF BONE MARROW MESENCHYMAL STROMAL CELLS REDUCES THE ACTIVITY ANKYLOSING SPONDYLITIS ASSOCIATED WITH CROHN'S DISEASE
TREATMENT OF BONE MARROW MESENCHYMAL STROMAL CELLS REDUCES THE ACTIVITY ANKYLOSING SPONDYLITIS ASSOCIATED WITH CROHN'S DISEASE

THE EFFECTIVENESS AND SAFENESS OF ALLOGENEIC MESENCHYMAL STROMAL CELLS OF BONE MARROW IN PATIENTS WITH REFRACTORY CROHN'S DISEASE - 10 YEARS OF OBSERVATION
THE EFFECTIVENESS AND SAFENESS OF ALLOGENEIC MESENCHYMAL STROMAL CELLS OF BONE MARROW IN PATIENTS WITH REFRACTORY CROHN'S DISEASE - 10 YEARS OF OBSERVATION

MICROSCOPIC COLITIS AND RISK OF INCIDENT PSORIASIS: A NATIONWIDE POPULATION-BASED MATCHED COHORT STUDY.
MICROSCOPIC COLITIS AND RISK OF INCIDENT PSORIASIS: A NATIONWIDE POPULATION-BASED MATCHED COHORT STUDY.

INTESTINAL ULTRASOUND IS RESPONSIVE TO TREATMENT IN NEWLY DIAGNOSED CROHN’S DISEASE
INTESTINAL ULTRASOUND IS RESPONSIVE TO TREATMENT IN NEWLY DIAGNOSED CROHN’S DISEASE

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

INFLAMMATORY BOWEL DISEASE IN THE LGBTIQ+ POPULATION: ESTIMATES OF PREVALENCE IN ENGLAND & WALES AND THE IMPLICATION FOR SERVICES
INFLAMMATORY BOWEL DISEASE IN THE LGBTIQ+ POPULATION: ESTIMATES OF PREVALENCE IN ENGLAND & WALES AND THE IMPLICATION FOR SERVICES

A RETROSPECTIVE ANALYSIS OF FAT COMPOSITION IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A RETROSPECTIVE ANALYSIS OF FAT COMPOSITION IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

INTESTINAL ULTRASOUND – COLITIS SEVERITY INDEX (IUS-CSI): VALIDATION OF AN INTESTINAL ULTRASOUND-BASED SCORE FOR ASSESSING DISEASE ACTIVITY IN ULCERATIVE COLITIS
INTESTINAL ULTRASOUND – COLITIS SEVERITY INDEX (IUS-CSI): VALIDATION OF AN INTESTINAL ULTRASOUND-BASED SCORE FOR ASSESSING DISEASE ACTIVITY IN ULCERATIVE COLITIS

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Item 721 - 740 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37
38 39 40 41 42